In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

A new report shows up to 7.2 million Americans aged 65 and older are living with Alzheimer’s disease, an increase of about 300,000 cases.

A new report from the Alzheimer's Association indicates people feel that the earlier they know about a diagnosis, the sooner they can seek treatment options.

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

A phase I/II trial showed that transplanting dopaminergic progenitors derived from induced pluripotent stem cells was safe in ...

Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...

Patients will lose access to cheaper versions of the blockbuster drugs after the agency shuts down the multibillion-dollar industry now that the drug shortage has ended. Also in the news: Eli Lilly's ...

Find insight on Abbott Laboratories, Sartorius and more in the latest Market Talks covering the Health Care sector.